Novartis AG
NVSEF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $14 | $15 | $14 | $14 |
| % Growth | -3.2% | 8.9% | 0.5% | – |
| Cost of Goods Sold | $4 | $3 | $3 | $3 |
| Gross Profit | $11 | $12 | $10 | $10 |
| % Margin | 75.4% | 77.6% | 76.3% | 75.5% |
| R&D Expenses | $3 | $3 | $2 | $3 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3 | $3 | $3 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6 | $7 | $6 | $7 |
| Operating Income | $5 | $5 | $5 | $4 |
| % Margin | 31.3% | 32.8% | 34.2% | 26% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $4 | $5 | $4 | $3 |
| Tax Expense | $0 | $1 | $1 | $0 |
| Net Income | $4 | $4 | $4 | $3 |
| % Margin | 27.4% | 27.2% | 26.9% | 20.8% |
| EPS | 2.02 | 2.07 | 1.83 | 1.42 |
| % Growth | -2.4% | 13.1% | 28.9% | – |
| EPS Diluted | 2 | 2.06 | 1.82 | 1.41 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $2 |
| EBITDA | $6 | $6 | $6 | $5 |
| % Margin | 40.7% | 41% | 42.8% | 38.3% |